This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Mechanism of Action DosingDosing InformationDose AdjustmentsDrug Interactions Trial Design & EfficacyTrial DesignEfficacySafety Profile & Tolerability  Support & ResourcesFrequently Asked QuestionsEducational ResourcesHCP Experience VideosNICE Guidance

Prescribing Information for PAXLOVID (nirmatrelvir / ritonavir) can be found here: Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page. Please note, there are differences between the SmPC for Northern Ireland and the SmPC for Great Britain. Please refer to the appropriate SmPC depending on where you are based.

Paxlovid has a Conditional Marketing Authorisation in Great Britain. A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.

NICE Guidance (TA878) on treatments for patients with COVID-1912024 NICE recommendations: expanded eligibility criteria allow a potential 15 million eligible high-risk adult patients access to COVID-19 treatment by June 2025.1,2View the NICE Guidance (TA878) here.1*

Paxlovid is now the only NICE-recommended treatment option for eligible select adult patient cohorts, and remains first line for eligible adult patients who do not need supplemental oxygen and are at increased risk of progression to severe COVID-19 as defined by the Independent Advisory Group Report.1,3
 

NICE recommended eligible cohorts for COVID-19 treatment:
                                                   Implementation: 13th June 2024 Implementation: 1st June 2025
PAXLOVID is the only treatment option:1 People aged > 85 years Aged > 70 years
  People resident in a care home or already hospitalised and:
  • Aged >70 years
  • or who have a BMI >35kg/m2
  • or have diabetes
  • or heart failure
Body mass index (BMI) of >35 kg/m2
People on the organ transplant waiting list Diabetes
People with end-stage heart failure who have long-term ventricular assistance devices Heart failure
 
PAXLOVID is recommended first line:1 Patients as defined by the Independent Advisory Group Report in Section 5 of NICE TA878* who are at greatest risk of progression to severe disease e.g. Immune mediated inflammatory disorders, certain cancers, immune deficiencies etc.1,4 

Visit the report for full details on which patients are considered to be at greatest risk of progression to severe disease.
 
•Sotrovimab is recommended second line if Paxlovid (nirmatrelvir/ritonavir) is contraindicated or unsuitable and if the company provides it according to the commercial arrangement1

The decision to treat and choice of treatment is based on the individual patient’s eligibility criteria, clinical circumstances and is ultimately at the discretion of the individual prescriber. Please refer to the relevant SmPC (GB or NI)5,6 before making any prescribing decisions. 


The staged rollout is due to NHS England's ambition to potentially protect the eligible highest risk adult patients while ensuring equitable access to treatment.1

 

Join us! 

Set up a PfizerPro account to access further materials and resources, and receive communication about medicines and vaccines promoted by Pfizer. 

Join now
Dosing Dosing Information Guide

Learn about PAXLOVID dosing, potential drug interactions, and how to prescribe.

Download Loading
GBEducational Resources

Explore downloadable materials to further support both you and your patients. 

Explore more
How PAXLOVID WorksLearn about how PAXLOVID inhibits replication by preventing proteolysis from occurring. Find out more

Explore more videos

Watch short educational key-opinion-leader (KOL) videos from Healthcare Professionals on their experience in managing patients at risk of severe COVID-19.

HCP Experience Videos
*Links to a third-party-website (outside of Pfizer). Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. Pfizer accepts no responsibility for the content or services of the linked site.

References:
1. National Institute for Health and Care Excellence (NICE). Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. TA878. Last updated: 13 March 2024. Available at: https://www.nice.org.uk/guidance/ta878/resources/nirmatrelvir-plus-ritonavir-sotrovimab-and-tocilizumab-for-treating-covid19-pdf-82613679870661* (accessed March 2024).
2.Mahase E. BMJ 2024;384:q59.
3. GOV.UK. Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report. Available at: https://www.gov.uk/government/publications/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report-march-2023* (accessed March 2024).
4. National Institute for Health and Care Excellence (NICE). TA878 Section 5: Supporting information on risk factors for progression to severe COVID‑19. Last updated: 13 March 2024. Available at: https://www.nice.org.uk/guidance/ta878/chapter/5-Supporting-information-on-risk-factors-for-progression-to-severe-COVID19* (accessed March 2024).
5. PAXLOVID® Summary of Product Characteristics. Great Britain.
6. PAXLOVID® Summary of Product Characteristics. Northern Ireland.
PP-C1D-GBR-0237. March 2024

Adverse Events
 

Adverse Events should be reported. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-C1D-GBR-0167. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​